SUNNYVALE, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and mediated diseases, today announced that it will report financial results for the fourth fiscal quarter and fiscal year ended June 30, 2010 after the NASDAQ Market closes on Monday, September 13, 2010. The company will conduct a conference call and an audio webcast at 4:30 p.m. EDT on the same day.
Additionally, the company announced that Dr. Ahmed Hamdy, Chief Medical Officer, will provide a corporate and clinical overview at The Stifel Nicolaus Healthcare Conference. The presentation will take place at the Four Seasons Hotel in Boston, Thursday, September 16, 2010 at 1:30 p.m. EDT. A link to the live webcast of the presentation that can be found at: http://ir.pharmacyclics.com/events.cfm.Fiscal Year End Quarter 2010 Conference Call and Webcast DetailsDate: September 13, 2010Time: 4:30 PM EDTListen via Internet: http://ir.pharmacyclics.com/events.cfmToll-free: +1-877-407-8133International: +1-201-689-8040A webcast replay will be available on the Pharmacyclics website for 30 days.
About PharmacyclicsPharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on exceptional scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate. We exist to make a difference for the better and these are important times to do just that.
Presently, Pharmacyclics has four product candidates in clinical development, a clinical development candidate in late stage pre clinical evaluation and several preclinical molecules in lead optimization. We are committed to high standards of ethics, scientific rigor, and operational efficiency as we move each of these programs to viable commercialization.
The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.Contact:Ramses ErdtmannVice President of FinancePhone: 408-215-3325
|SOURCE Pharmacyclics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved